Mepolizumab as an effective treatment in a case of hypophysitis in eosinophilic granulomatosis with polyangiitis.
| Autor: | Chen J; Department of Neurology and Experimental Neurology, Charité Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.; Experimental and Clinical Research Center, Charité Universitätsmedizin Berlin, Berlin, Germany., Alexander T; Department of Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany., Walter-Rittel T; Department of Radiology, Charité Universitätsmedizin Berlin, Berlin, Germany., Ziagaki A; Department of Endocrinology, Charité Universitätsmedizin Berlin, Berlin, Germany., Siffrin V; Department of Neurology and Experimental Neurology, Charité Universitätsmedizin Berlin, Berlin, Germany.; Clinician Scientist Program, Berlin Institute of Health, Berlin, Germany. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Therapeutic advances in neurological disorders [Ther Adv Neurol Disord] 2023 Jun 22; Vol. 16, pp. 17562864231182519. Date of Electronic Publication: 2023 Jun 22 (Print Publication: 2023). |
| DOI: | 10.1177/17562864231182519 |
| Abstrakt: | Granulomatosis or eosinophilic granulomatosis with polyangiitis (GPA/EGPA) can affect multiple organs resulting in heterogeneous symptoms and phenotypes. Pituitary gland dysfunction rarely occurs in GPA (1-3%) and even less in EGPA (two case reports). Here, we report a case of a 51-year-old female patient with a four-year history of EGPA who presented with new polydipsia and polyuria. Laboratory testing and magnetic resonance imaging (MRI) confirmed pituitary gland dysfunction caused by a hypophysitis. Therapeutic adjustment with a switch from dupilumab to mepolizumab resulted in a decrease in clinical symptoms, inflammation in MRI, and normalization of C-reactive protein in serum. This case underlines hypophysitis as a rare organ involvement also in EGPA. Moreover, this case demonstrates the responsiveness of neuroinflammatory manifestations to the recently approved anti-interleukin-5 monoclonal antibody mepolizumab as a new potential treatment option. Competing Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. (© The Author(s), 2023.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|